Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02338232 · ClinicalTrials.gov registry record · NA
Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
A NA study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT02338232 is a NA study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 32 participants.
The verdict
NCT02338232, a NA study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is single-center, open-label, prospective study of telmisartan for the prevention of acute GVHD in approximately 60 subjects undergoing allogeneic HCT for treatment of a hematologic malignancy.
Interventions
- DRUG Telmisartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-07-07 |
| Est. Completion | 2023-01-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02338232
The ClinicalTrials.gov registry entry for NCT02338232 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telmisartan is the first listed.
NCT02338232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02338232 about?
NCT02338232 is a clinical study titled "Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation". This is single-center, open-label, prospective study of telmisartan for the prevention of acute GVHD in approximately 60 subjects undergoing allogeneic HCT for treatment of a hematologic malignancy.
What is the current status of trial NCT02338232?
This trial is currently terminated. It is a NA study. The enrollment target is 32 participants. The study started on 2015-07-07. Estimated completion is 2023-01-05.
What interventions are being tested in trial NCT02338232?
The interventions under investigation include: Telmisartan (DRUG).
Who is sponsoring clinical trial NCT02338232?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.